Transient Mydriasis under Atomoxetine Treatment: Case Report and Brief Overview of the Literature

• References

• 1 Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics 2012; 9: 490-499
• 2 Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother 2014; 48: 209-225
• 3 Cascade EF, Kalali AH, Feifel D. Strattera: ups, downs, and emerging uses. Psychiatry 2007; 4: 23-25
• 4 Spiller HA, Hays HL, Aleguas jr. A. Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management. CNS Drugs 2013; 27: 531-543
• 5 Caglayan HZ, Colpak IA, Kansu T. A diagnostic challenge: dilated pupil. Curr Opin Ophthalmol 2013; 24: 550-557
• 6 Alhatem FJ, Decker DH. Atomoxetine-induced mydriasis. J Child Adolesc Psychopharmacol 2008; 18: 539-541
• 7 Bahali K, Ipek H, Yalcin O. et al. Atomoxetine-induced mydriasis in a child patient. Eur Child Adolesc Psychiatry 2014; 23: 1231-1232